<DOC>
	<DOCNO>NCT02160652</DOCNO>
	<brief_summary>A single center single arm prospective study , assess outcome ureteral re-implantation malignant ureteral obstruction .</brief_summary>
	<brief_title>Ureteral Reimplantation Treatment Extrinsic Malignant Ureteral Obstruction</brief_title>
	<detailed_description>The Research Question : Is laparoscopic ureteral re-implantation , treatment malignant ureteral obstruction , associate high patency rate , low complication rate , significant improvement quality life ? Study design : A single center single arm prospective study , assess outcome ureteral re-implantation malignant ureteral obstruction . Study population : Patients malignant ureteral obstruction , treat laparoscopic ureteral re-implantation , life expectancy 6 month willing able participate study . Intervention : Laparoscopic ureteral re-implantation . Study Time line : This 1 year study . At initiation baseline physical exam , blood test , ultrasonography perform . Baseline quality life questionnaire fill . After operation , Follow-up visit occur 1 , 3 , 6 12 month surgery . At follow visit medical history physical examination , blood test quality life questionnaire perform . At 3 , 6 12 month renal ultrasonography perform . Primary Endpoint : Ureteral patency 6 month follow treatment - assess stable improve hydronephrosis estimate glomerular filtration rate ( eGFR ) accord Chronic Kidney Disease Epidemiology Collaboration ( CKD-EPI ) equation . Study impact : Current treatment malignant ureteral obstruction nephrostomy tube negatively impact patient 's quality life . The finding current study may support use laparoscopic ureteral re-implantation treatment malignant ureteral obstruction , patency preserve , quality life improve , follow procedure .</detailed_description>
	<mesh_term>Ureteral Obstruction</mesh_term>
	<criteria>Inclusion criterion : 1 . Adult patient , old 18 year age . 2 . Patient malignant ureteral obstruction diagnose creatinine elevation evidence ureteral obstruction imaging . 3 . Patient schedule ureteral reimplantation due extrinsic malignant ureteral obstruction . 4 . American Society Anesthesiologist score â‰¤3 , enable patient undergo surgery . 5 . Life expectancy 6 month ( see exclusion criterion definition ) 6. WHO performance status 02 7 . The patient willing able read , understand sign study specific informed consent form Exclusion criterion : 1 . Patients underwent urinary diversion percutaneous nephrostomy retrograde ureteral stenting prior plan treatment . 2 . Patients unable sign inform consent unwilling undergo . 3 . Life expectancy le 6 month , define accord criterion Ishioka et al . predict presence : Low serum albumin percutaneous nephrostomy/ retrograde ureteral stenting ( 3 gm/dl less ) . Low grade hydronephrosis prior percutaneous nephrostomy/ retrograde ureteral stenting placement ( grade 1 2 ) grade grade system Society Fetal Urology Malignant ascites malignant pleural effusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Ureteral Obstruction</keyword>
	<keyword>HYDRONEPHROSIS</keyword>
	<keyword>nephrostomy tube</keyword>
</DOC>